JP Morgan Maintains Overweight on Roivant Sciences, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has maintained an Overweight rating on Roivant Sciences (NASDAQ:ROIV) but reduced the price target from $16 to $15.

November 14, 2023 | 6:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan has maintained its Overweight rating on Roivant Sciences but lowered the price target from $16 to $15.
While the reduction in price target could suggest a slightly less optimistic outlook on the stock's valuation, maintaining an Overweight rating indicates a continued positive view on the company's prospects. The impact on the stock price is likely to be neutral in the short term as the rating affirmation balances the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100